Core Insights - Sona Nanotech Inc. reported an 80% response rate in its first-in-human clinical study of Targeted Hyperthermia Therapy (THT) for treating immunotherapy-resistant cutaneous metastatic melanoma, with six out of ten patients achieving complete responses and two showing partial responses within two weeks of treatment [1][2] Group 1: Clinical Study Results - The study involved ten advanced-stage melanoma patients who were not responding to standard immunotherapy, with eight patients showing significant clinical responses by day 15 [1][2] - Six out of the eight responding patients had no detectable residual melanoma in biopsied tumors, while two patients did not respond [1][2] - The rapid response observed in patients has provided meaningful hope for those who had exhausted standard treatment options [2] Group 2: Future Plans and Development - Based on the study findings, the company is preparing for a Canadian clinical trial to explore the biological potential of THT in a broader range of solid tumors, with an application for investigational testing authorization submitted to Health Canada [2] - The company aims to enhance the design and application of THT based on clinician-reported and patient-reported experiences captured during the study [2] Group 3: Safety and Tolerability - Safety data indicated favorable results, with one serious adverse event deemed unrelated to THT and resolved, while two patients expired due to disease progression [2] - The study's outcomes validate earlier preclinical findings and provide compelling evidence of THT's efficacy and tolerability in human cancer treatment [2][3] Group 4: Company Background - Sona Nanotech is focused on developing Targeted Hyperthermia, a photothermal cancer therapy that utilizes therapeutic heat to treat solid tumors, aiming to stimulate the immune system and improve drug delivery to tumors [4][5]